Grademi Biotech Srl
Bologna
About Grademi Biotech Srl
Grademi Biotech is developing a patented device, X10 Pathology to enhance the diagnostic value of ESR testing. The erythrocyte sedimentation rate (ESR) is a widely used non-specific blood test for inflammation, used to help support the diagnosis of a wide range of diseases and monitor therapy. X10 Pathology correlates ESR rate in plasma to specific disease states creating new functionality and dramatically improved performance. This allows: more rapid and specific disease diagnosis; reduced need for additional diagnostic testing and improve disease monitoring. The X10 Pathology is undergoing validation testing at a leading hospital in Italy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $55.8K
- Last round: Grant (Aug 2016)
- Website: grademi.comen
- Phone: +39.051.6781083
Industries & Categories
Biotechnology, Life Science, Medical
Canonical: https://fsome.com/organization/grademi-biotech-srl-2202892 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.